Analyst Price Target is $94.11
▲ +71.30% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Praxis Precision Medicines in the last 3 months. The average price target is $94.11, with a high forecast of $170.00 and a low forecast of $28.00. The average price target represents a 71.30% upside from the last price of $54.94.
Current Consensus is
Moderate Buy
The current consensus among 9 polled investment analysts is to moderate buy stock in Praxis Precision Medicines. This Moderate Buy consensus rating has held steady for over two years.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Read More
